Planning and Feasibility · V&V Testing & Lab Management
Architect a "Test-Once, Submit-Globally" V&V testing program.
Testing against superseded standard editions, omitting IEC 60601-2-x particular standards, or failing to define Essential Performance upfront invalidates months of lab work. We engineer a unified V&V testing matrix across ILAC-MRA, IECEE CB, and OECD GLP laboratories.
Domain Expertise
Deep regulatory authority across every medical device domain
SaMD · AI Digital Health
IEC 62304 & IEC 82304-1 Software Lifecycle · FDA PCCP & Good Machine Learning Practice
Multi-demographic dataset bias control and statistical validation design for Sensitivity, Specificity, and ROC-AUC
Active Devices · Robotics
IEC 60601-1 Ed. 3.2 & IEC 60601-1-2 Ed. 4.1 · IEC 60601-2-XX Particular Standards
Essential Performance definition and worst-case test matrix optimization across FDA, EU Notified Bodies, and MDSAP
Implants · Biomaterials
ISO 10993-1:2018 & ISO 10993-18 E&L · ISO 11135 / 11137 Sterilization & ISO 11607
Biological evaluation plans (BEP), ISO 10993-18 chemical characterization, and toxicological risk assessment (TRA)
In Vitro Diagnostics (IVD)
EU IVDR 2017/746 & FDA IVD Guidance · CLSI EP Guidelines (EP05, EP06, EP12, EP17, EP25)
CLSI-compliant Limit of Detection (LoD), precision, cross-reactivity, interference, and lot-to-lot reproducibility protocols
Proprietary Data & Precedent Validation
Global Standard & National Deviation Matrix + Accredited Lab Capacity DB
100% Optimization of Multi-Market Test Matrices & Worst-Case Sample Grouping
Engineered 4-Stage Workflow
4-Stage Testing Pipeline from Master Test Plan to Audited Final TRFs
Master Multi-Region Test Matrix, Essential Performance & Sample Plan Locked
Incomplete baseline data or misclassified regulatory pathways are the primary drivers of multi-month submission delays. Gate 01 locks the device scope, predicate/standard mapping, and full document inventory before authoring begins.
Verification Baseline
Device description, intended use, existing test reports, and QMS document index
Gate Sign-Off Output
Confirmed classification matrix and locked submission master inventory
Agentic Automation & Platform Integration
Sync Test Protocols & TRFs Directly with PLM V&V and ISO 14971 Risk Controls
Bi-Directional Mapping: Test Clause ↔ Design Output ↔ Risk Control
Automatically links accredited laboratory test results to PLM verification records and ISO 14971 risk control effectiveness proofs.
@Requirements Management— Run "Bi-Directional Mapping: Test Clause ↔ Design Output ↔ Risk Control" across our V&V Testing & Lab Management records and call out the highest-priority compliance findings first.
I'll inspect the linked quality and dossier records against target regulatory standards, then report actionable findings with verified outputs.
Thought for 4.2s · Explored Requirements Management records & 14 regulatory clauses
Automatically links accredited laboratory test results to PLM verification records and ISO 14971 risk control effectiveness proofs. Traceability from specification to verification
Test Sample BOM, Firmware Revision & Configuration Lock
Records the exact hardware BOM and software build of tested units so reviewers never question sample representativeness.
@Risk Management— Run "Test Sample BOM, Firmware Revision & Configuration Lock" across our V&V Testing & Lab Management records and call out the highest-priority compliance findings first.
I'll inspect the linked quality and dossier records against target regulatory standards, then report actionable findings with verified outputs.
Thought for 4.3s · Explored Risk Management records & 14 regulatory clauses
Verifies model nomenclature, electrical ratings, Essential Performance pass criteria, and accreditation seals before final TRF sign-off. ISO 14971 risk register linked to design control
Service Specification
Service Scope & Final Deliverables
Scope
End-to-end engineering management from standard mapping and worst-case sample selection to failure debugging and report sign-off.
- Multi-market standard & National Deviation mapping (IEC 60601-1/1-2, IEC 60601-2-XX, ISO 10993, ISO 11607, CLSI)
- Worst-case model family grouping and sample quantity optimization to minimize laboratory spend and lead times
- Accredited laboratory sourcing, quote benchmarking, and slot reservation (IECEE CBTL, ILAC-MRA, FDA ASCA, GLP)
- Essential Performance definition and pre-compliance test protocol engineering
- Real-time bench failure root-cause debugging and line-by-line regulatory audit of draft Test Report Forms (TRFs)
Deliverables
Submission-ready test evidence engineered for first-cycle acceptance across global regulatory bodies.
- Global Master Test Standard & National Deviation Matrix
- Worst-Case Sample Grouping Rationale & Essential Performance Specification
- Accredited Laboratory Comparison Matrix & Locked Test Protocols
- Engineering Failure Resolution & Re-Test Logs (if applicable)
- Regulatory-Audited Final IECEE CB / ILAC-MRA / GLP Test Report Package
| Category | Item / Milestone | Specification & Deliverable |
|---|---|---|
| Scope | Scope 1 | Multi-market standard & National Deviation mapping (IEC 60601-1/1-2, IEC 60601-2-XX, ISO 10993, ISO 11607, CLSI) |
| Scope | Scope 2 | Worst-case model family grouping and sample quantity optimization to minimize laboratory spend and lead times |
| Scope | Scope 3 | Accredited laboratory sourcing, quote benchmarking, and slot reservation (IECEE CBTL, ILAC-MRA, FDA ASCA, GLP) |
| Scope | Scope 4 | Essential Performance definition and pre-compliance test protocol engineering |
| Scope | Scope 5 | Real-time bench failure root-cause debugging and line-by-line regulatory audit of draft Test Report Forms (TRFs) |
| Workflow | Stage 1: Master Test Matrix & Essential Performance Lock | Consolidate target market standard editions and National Deviations while defining Essential Performance and worst-case test samples. |
| Workflow | Stage 2: Accredited Lab Allocation & Protocol Sign-Off | Benchmark accredited laboratories on scope, cost, and queue time, then lock the formal Test Plan before sample shipment. |
| Workflow | Stage 3: Active Test Supervision & Failure Debugging | Interface directly with lab engineers during EMC, safety, biocompatibility, and performance runs to resolve anomalies without losing queue slots. |
| Workflow | Stage 4: Draft TRF Regulatory Audit & Final Release | Audit draft reports for model nomenclature, firmware revisions, test conditions, and clause completeness before final issuance. |
| Deliverables | Deliverable 1 | Global Master Test Standard & National Deviation Matrix |
| Deliverables | Deliverable 2 | Worst-Case Sample Grouping Rationale & Essential Performance Specification |
| Deliverables | Deliverable 3 | Accredited Laboratory Comparison Matrix & Locked Test Protocols |
| Deliverables | Deliverable 4 | Engineering Failure Resolution & Re-Test Logs (if applicable) |
| Deliverables | Deliverable 5 | Regulatory-Audited Final IECEE CB / ILAC-MRA / GLP Test Report Package |
Frequently Asked Questions
What types of testing do you manage?
Do you perform the tests yourselves?
Can you review a test program that already started?
When should we start testing management?
How does Leanabl handle agency Additional Information (AI) requests or Notified Body deficiency letters during V&V Testing & Lab Management?
Can we structure one master DHF / IMDRF STED and test campaign to cover FDA, EU MDR, and APAC markets simultaneously?
We have a lean internal RA/QA team—how much bandwidth is required from our R&D engineers?
What happens if our hardware, firmware, or software changes during or after the engagement?
Know the test plan before samples leave your site.
We define the route, evidence gaps, sequencing, and decision points before labs, samples, and timelines start moving.